Trial Outcomes & Findings for Sacral Nerve Stimulation in Treating Low Anterior Resection Syndrome or Fecal Incontinence in Patients With Locally Advanced Rectal Cancer or Other Pelvic Cancer, the RESTORE Study (NCT NCT04066894)

NCT ID: NCT04066894

Last Updated: 2023-08-14

Results Overview

SNS success will be measured as a patient having the battery implanted at visit 3. Patients who do not have the SNS placed, for any reason other than insurance coverage issues, will count as not having a success. Fecal incontinence will be measured by the physician as the total number of gas, mucus, liquid stool, and solid stool accidental leakage events reported in the bowel diaries. Improvement will be determined by the physician based on bowel diary comparisons recorded before SNS lead placement at visit 1 to after lead placement at visit 2. The proportion of patients who experience SNS success will be reported with a 90% credible interval using a beta (1,1)

Recruitment status

TERMINATED

Study phase

PHASE2

Target enrollment

3 participants

Primary outcome timeframe

Up to visit 3

Results posted on

2023-08-14

Participant Flow

Participant milestones

Participant milestones
Measure
Experimental: Sacral Nerve Stimulation (SNS)
Patients undergo scheduled, elective surgery for placement of the sacral nerve stimulator with external battery pack. After 2 weeks, patients undergo implantation of a subcutaneous internal battery or removal of the leads if the sacral nerve stimulator is working but does not improve symptoms. If the sacral nerve stimulator is not working, it is repositioned and patients return 2 weeks later for implantation of external battery or removal of leads.
Overall Study
STARTED
3
Overall Study
COMPLETED
1
Overall Study
NOT COMPLETED
2

Reasons for withdrawal

Reasons for withdrawal
Measure
Experimental: Sacral Nerve Stimulation (SNS)
Patients undergo scheduled, elective surgery for placement of the sacral nerve stimulator with external battery pack. After 2 weeks, patients undergo implantation of a subcutaneous internal battery or removal of the leads if the sacral nerve stimulator is working but does not improve symptoms. If the sacral nerve stimulator is not working, it is repositioned and patients return 2 weeks later for implantation of external battery or removal of leads.
Overall Study
Lack of Efficacy
1
Overall Study
Screen Failure
1

Baseline Characteristics

Sacral Nerve Stimulation in Treating Low Anterior Resection Syndrome or Fecal Incontinence in Patients With Locally Advanced Rectal Cancer or Other Pelvic Cancer, the RESTORE Study

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Experimental: Sacral Nerve Stimulation (SNS)
n=3 Participants
Patients undergo scheduled, elective surgery for placement of the sacral nerve stimulator with external battery pack. After 2 weeks, patients undergo implantation of a subcutaneous internal battery or removal of the leads if the sacral nerve stimulator is working but does not improve symptoms. If the sacral nerve stimulator is not working, it is repositioned and patients return 2 weeks later for implantation of external battery or removal of leads.
Age, Categorical
<=18 years
0 Participants
n=5 Participants
Age, Categorical
Between 18 and 65 years
3 Participants
n=5 Participants
Age, Categorical
>=65 years
0 Participants
n=5 Participants
Sex: Female, Male
Female
2 Participants
n=5 Participants
Sex: Female, Male
Male
1 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
2 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
1 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=5 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=5 Participants
Race (NIH/OMB)
Asian
0 Participants
n=5 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=5 Participants
Race (NIH/OMB)
Black or African American
0 Participants
n=5 Participants
Race (NIH/OMB)
White
1 Participants
n=5 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=5 Participants
Race (NIH/OMB)
Unknown or Not Reported
2 Participants
n=5 Participants
Region of Enrollment
United States
3 participants
n=5 Participants

PRIMARY outcome

Timeframe: Up to visit 3

Population: No data was collected

SNS success will be measured as a patient having the battery implanted at visit 3. Patients who do not have the SNS placed, for any reason other than insurance coverage issues, will count as not having a success. Fecal incontinence will be measured by the physician as the total number of gas, mucus, liquid stool, and solid stool accidental leakage events reported in the bowel diaries. Improvement will be determined by the physician based on bowel diary comparisons recorded before SNS lead placement at visit 1 to after lead placement at visit 2. The proportion of patients who experience SNS success will be reported with a 90% credible interval using a beta (1,1)

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Up to 3 years

Population: No data was collected

Will be reported descriptively with graphs or tabulations for categorical survey outcomes.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Up to 3 years

Population: No data was collected

Will be reported descriptively with graphs or tabulations for categorical survey outcomes.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Up to 3 years

Population: No data was collected

Will be reported descriptively with graphs or tabulations for categorical survey outcomes.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Up to 3 years

Population: No data was collected

Will be reported descriptively with graphs or tabulations for categorical survey outcomes.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Up to 3 years

Population: No data was collected

Will be reported descriptively with graphs or tabulations for categorical survey outcomes.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Up to 3 years

Population: No data was collected

Will be reported descriptively with graphs or tabulations for categorical survey outcomes.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Up to 3 years

Population: No data was collected

Will be reported descriptively with graphs or tabulations for categorical survey outcomes.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Up to 30 days (visit 2)

Population: No data was collected

Will be measured using bowel diaries.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Up to 30 days (visit 2)

Population: No data was collected

Will be measured using bladder diaries and a post-void urinary bladder residual and validated urinary symptom questionnaire.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Up to 3 years

Population: No data was collected

Will be reported descriptively with graphs or tabulations for categorical survey outcomes.

Outcome measures

Outcome data not reported

Adverse Events

Experimental: Sacral Nerve Stimulation (SNS)

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Dr. Craig Messick

M D Anderson Cancer Center

Phone: (713) 745-1544

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place